- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 19
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 19.
Number 5: A white paper from the Association for Accessible Medicines says that brand-name drug products are behind high prescription drug costs, and that those high costs endanger patients’ health.
Number 4: At last week’s 13th annual congress of the European Crohn's and Colitis Organisation, researchers presented findings from several studies investigating the efficacy of 2 biosimilar infliximab products.
Number 3: Investigators have released data from a 26-week open label extension of the NOR-SWITCH trial in patients with inflammatory bowel disease.
Number 2: The Patients for Biologic Safety and Access, a patient advocacy group, called on the FDA to revise its materials on biosimilars. However, some patient groups are calling PBSA’s stance into question.
Number 1: Express Scripts and Walgreens Boots are expanding their purchasing efforts to include specialty medications, such as biologics and biosimilars.
Also this week, contributor Amanda Forys, of Xcenda, explained what biosimilar manufacturers need to know about changes to the 340B Drug Pricing Program.
Finally, last week, our e-newsletter asked for your thoughts on when nonmedical substitution will become a reality in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
